Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 7.8% – Time to Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was up 7.8% during mid-day trading on Monday . The company traded as high as $27.30 and last traded at $27.09. Approximately 142,627 shares were traded during trading, a decline of 51% from the average daily volume of 290,740 shares. The stock had previously closed at $25.12.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on DNTH shares. Oppenheimer upped their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, November 11th. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating for the company. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Performance

The firm’s fifty day simple moving average is $24.61 and its 200 day simple moving average is $26.59. The stock has a market capitalization of $757.09 million, a P/E ratio of -10.23 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DNTH. Barclays PLC boosted its stake in shares of Dianthus Therapeutics by 390.5% in the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after purchasing an additional 33,185 shares in the last quarter. Jane Street Group LLC acquired a new stake in Dianthus Therapeutics in the third quarter valued at approximately $556,000. Wellington Management Group LLP bought a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at $1,473,000. State Street Corp increased its holdings in Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after purchasing an additional 413,425 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its stake in shares of Dianthus Therapeutics by 151.3% during the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after purchasing an additional 263,500 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.